-2%
Drometa contains Zoledronic acid, a nitrogen-containing bisphosphonate with potent antiresorptive properties. It acts by inhibiting osteoclast-mediated bone breakdown, a process crucial in conditions like metastases and osteoporosis. Zoledronic acid has a high affinity for bone mineral, allowing it to localize to areas of active bone remodeling.
Its primary mode of action involves inhibition of farnesyl pyrophosphate synthase in the osteoclasts, disrupting the mevalonate pathway essential for osteoclast function. This leads to decreased bone resorption and turnover. Moreover, Zoledronic acid also exhibits antitumor, antiangiogenic, analgesic, cytostatic, and pro-apoptotic effects, and may enhance the efficacy of other chemotherapeutics. It is not metabolized and is eliminated unchanged by the kidneys.
Drometa is indicated for the management and treatment of various bone-related conditions, particularly where there is excessive bone resorption. Its clinical uses include:
- Hypercalcemia associated with malignancy
- Bone metastases secondary to solid tumors
- Osteolytic lesions in multiple myeloma
- Corticosteroid-induced osteoporosis
- Osteoporosis in postmenopausal women
- Osteoporosis in men with low bone mass
- Paget’s disease of bone
- Prevention of postmenopausal osteoporosis